Q-omics provides the consensus-scored NBPF10 profile across patient tissues and cancer cell-line models. NBPF10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NBPF10 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NBPF10 RNA expression shows 20,041 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, KIRC, and KIRP as cancer lineages where NBPF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF10 survival associations across molecular data types. NBPF10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF10 RNA expression–survival associations across cancer types. High NBPF10 expression shows unfavorable associations in ACC, OV, COAD, UVM and LUAD, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NBPF10 RNA expression.
This table summarizes NBPF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF10 shows lower tumor expression in UCEC and THCA and higher tumor expression in KIRC, LIHC, KIRP and CHOL. The KIRC box plot shows higher NBPF10 RNA expression in tumor versus normal tissue (log2 FC = +0.146, t-test p < 0.001).
This table shows molecular features associated with NBPF10 in patient tissues and cancer cell lines. In patient samples, NBPF10 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
